Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC‐UV detection

Yonemoto, Haruo; Ogino, Seiko; Nakashima, Mihoko N.; Wada, Mitsuhiro; Nakashima, Kenichiro

doi:10.1002/bmc.759

Cited by 28 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, PEGylated NP administered at a dose of 150 μg PTX (corresponding to 0.35 mg/kg) gave 4 and 10 times higher PTX plasma levels 20 min and 6 h after injection, respectively, than those observed in rat studies by others with 1.0 mg/kg PTX administered intraarterially (26). These findings are in agreement with the "stealth" properties of PEGylated NP (Fig.…”

Section: Discussionsupporting

confidence: 81%

Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields

Chorny

Fishbein

Yellen

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

188

156

View full text Add to dashboard Cite

The use of stents for vascular disease has resulted in a paradigm shift with significant improvement in therapeutic outcomes. Polymer-coated drug-eluting stents (DES) have also significantly reduced the incidence of reobstruction post stenting, a disorder termed in-stent restenosis. However, the current DESs lack the capacity for adjustment of the drug dose and release kinetics to the disease status of the treated vessel. We hypothesized that these limitations can be addressed by a strategy combining magnetic targeting via a uniform field-induced magnetization effect and a biocompatible magnetic nanoparticle (MNP) formulation designed for efficient entrapment and delivery of paclitaxel (PTX). Magnetic treatment of cultured arterial smooth muscle cells with PTX-loaded MNPs caused significant cell growth inhibition, which was not observed under nonmagnetic conditions. In agreement with the results of mathematical modeling, significantly higher localization rates of locally delivered MNPs to stented arteries were achieved with uniform-field-controlled targeting compared to nonmagnetic controls in the rat carotid stenting model. The arterial tissue levels of stent-targeted MNPs remained 4-to 10-fold higher in magnetically treated animals vs. control over 5 days post delivery. The enhanced retention of MNPs at target sites due to the uniform field-induced magnetization effect resulted in a significant inhibition of in-stent restenosis with a relatively low dose of MNP-encapsulated PTX (7.5 μg PTX/stent). Thus, this study demonstrates the feasibility of site-specific drug delivery to implanted magnetizable stents by uniform fieldcontrolled targeting of MNPs with efficacy for in-stent restenosis.angioplasty | biodegradable nanoparticles | magnetic targeting | restenosis | rat model

show abstract

Section: Discussionsupporting

confidence: 81%

Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields

Chorny

Fishbein

Yellen

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

188

156

View full text Add to dashboard Cite

show abstract

“…Not only assays for single taxane quantification are developed using HPLC-UV, but also assays for combined quantification of docetaxel, paclitaxel and other drugs [49][50][51], and assays for quantification of parent drugs and metabolites [52][53][54]. Most assays quantify taxanes in human or rodent plasma, although some assays have been designed for quantification of taxanes in serum [18,19,37], tissue [22,54], urine [21,26,28,29,41,48,54] or feces [54].…”

Section: Hplc-uvmentioning

confidence: 99%

Quantification of Taxanes in Biological Matrices: A Review of Bioanalytical Assays and Recommendations for Development of New Assays

et al. 2014

View full text Add to dashboard Cite

Since the isolation of paclitaxel and its approval for the treatment of breast cancer, various taxanes and taxane formulations have been developed. To date, almost 100 bioanalytical assays have been published with the method development and optimization often extensively discussed by the authors. This Review presents an overview of assays published between January 1970 and September 2013 that described method development and validation of assays used to quantify taxanes in biological matrices such as plasma, urine, feces and tissue samples. For liquid chromatography assays, sample pretreatment, chromatographic separation and assay performance are compared. Since this Review discusses the limitations of previously developed liquid chromatography assays and gives recommendations for future assay development, it can be used as a reference for future development of liquid chromatography assays for the quantification of taxanes in various biological matrices to support preclinical and clinical studies.

show abstract

“…This drug moves to block mitotic activity through interference with the formation of microtubules [29], thus preventing cancer cell division. However, due to the prevalence of significant side effects, paclitaxel is almost always used in a comparatively low dose to other bioactive agents [30]. This need for a precise window of treatment combined with the important nature of the drugs indications make paclitaxel an important drug for quantification.…”

Section: Metronidazolementioning

confidence: 99%

“…This need for a precise window of treatment combined with the important nature of the drugs indications make paclitaxel an important drug for quantification. HPLC is uniquely suited for the low levels of drug used as well as the common use of paclitaxel with other drugs and excipients such as Chremophor EL ® [28][29][30][31]. The hydrophobic nature of the drug does necessitate different mobile phase ratios than other drugs described, but hydrophobic columns can be used and detection is usually around 230 nm [28][29][30][31].…”

Section: Metronidazolementioning

confidence: 99%

Development and Utilization of Reversed Phase High Performance Liquid Chromatography Methods for a Series of Therapeutic Agents

Corbett¹

2013

Mod Chem Appl

View full text Add to dashboard Cite

Capability to quantify drug release is vital in many areas of pharmaceutical research. Accurate, rapid and repeatable detection of pharmaceutical agents allows for comparisons between drug delivery constructs prior to in vivo studies as well as identification of therapeutic levels in samples both in vitro and in vivo. Perhaps the foremost scientific method for monitoring of therapeutics is High Performance Liquid Chromatography. This process allows for clear and simple quantification of therapeutic presence in a sample, with an inherent or induced chromophore, through the detection of bound specimen to the utilized column. Multiple drugs can be used through this process and exemplary methods are presented for the pharmaceutics; cefuroxime, clindamycin, dexamethasone, dicloxacillin, doxycycline, metronidazole, oxymetazoline, paclitaxel, tobramycin, and vancomycin. Each of these drugs is analyzed using Reversed-Phase High Performance Liquid Chromatography utilizing a hydrophobic column. Independent, repeatable methods are developed for each drug. Where necessary a pre-column derivatization is used to allow for visualization of otherwise undetectable tobramycin. In the case of each drug, a standard curve is presented to show the linearity of response for the proposed method within a range of absorbance. This work shows the ability to analyze multiple drugs with a single simple, quick, cost effective system and detection methods are evaluated for each drug with a R 2 value of greater than 0.99.

show abstract

Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC‐UV detection

Cited by 28 publications

References 24 publications

Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields

Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields

Quantification of Taxanes in Biological Matrices: A Review of Bioanalytical Assays and Recommendations for Development of New Assays

Development and Utilization of Reversed Phase High Performance Liquid Chromatography Methods for a Series of Therapeutic Agents

Contact Info

Product

Resources

About